DRTS - Cancer Goes Bye Bye / Portfolio Goes High High
DRTS uses radium-224 alpha particles to attack tumors directly regardless of genetic markers or protein expression, demonstrating impressive early results in glioblastoma, pancreatic, and skin cancers. The company has FDA breakthrough device designation and regulatory advantage as a device rather than drug, with significant market value potential if the technology proves durable and scalable across multiple solid tumor types.